The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication

In brief

The purpose of this study is to conduct an interventional, one year, randomized, double blind, placebo-controlled trial with Liraglutide in patients with type 2 diabetes (diabetes duration of \>6 months and \<10 years, HbA1c \<10%) to evaluate its effects on the peripheral autonomic nervous system, as well as inflammatory markers, and measures of oxidative and nitrosative stress.

Key facts

Study ID

NCT03426085

Run by

Eastern Virginia Medical School

People needed

44

Starts

2016-05-01

Expected to finish

2020-08-01

Last updated by the study team

2019-02-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• established type 2 diabetes (diabetes duration of >6 months and <10 years).
• Age 18-80 years
• HbA1c at screening ≤ 10%
• Subjects on stable (≥3 months prior to Screening) Standard of Care background diabetic therapy. Diabetic treatment regimens include diet and exercise alone or in association with oral anti-diabetic drugs (monotherapy or combinations) and/or long-acting insulin.

You may not qualify if…

• Presence of type 1 diabetes mellitus (defined as C-peptide <1 ng /ml, <35y and prone to ketoacidosis)
• Treatment with rapid-acting or short-acting insulin within the last 3 months
• Proliferative retinopathy or maculopathy requiring acute treatment
• Impaired renal function , defined as serum creatinine ≥ 125 µmol/L (≥1.4 mg/dL) for males and ≥ 110 µmol/L (≥1.24 mg/dL) for females
• Impaired liver function, defined as aspartate transaminase (AST) or alanine transaminase (ALT), ≥ 2.5 times the upper limit of normal
• Presence of clinically significant peripheral or autonomic neuropathy that is clearly of non-diabetic origin
• Uncontrolled treated/untreated hypertension (systolic blood pressure (BP) ≥180 or diastolic blood pressure (BP) ≥100 at screening)
• Clinically significant active macrovascular disease including myocardial infarction or cerebrovascular event within the past 6 months. Other exclusions include coronary artery bypass graft or coronary angioplasty in the previous 3 months, unstable angina pectoris (chest pain at rest, worsening chest pain, or admission to the emergency room (ER) or hospital for chest pain) within the previous 3 months, and/or congestive heart failure (NYHA Class III-IV)
• Subjects known to be Hepatitis B surface antigen or Hepatitis C antibody positive with active hepatitis.
• Active infection (e.g., human immunodeficiency virus (HIV), hepatitis), or a history of severe infection during the 30 days prior to screening
• Evidence of immunocompromised status, including but not limited to individuals who have undergone organ transplantation, who are known to be HIV positive, or who are taking immunosuppressive drugs or chronic systemic corticosteroid treatment.
• Major surgical procedure during the 30 days prior to screening
• Diagnosis and/or treatment of malignancy (except for basal cell or squamous cell skin cancer, in-situ carcinoma of the cervix, or in-situ prostate cancer) within the past 5 years
• Known clinically significant gastric emptying abnormality (e.g. severe gastroparesis), or history of gastric bypass (bariatric) surgery
• Thyroid stimulating hormone (TSH) outside of normal limits at screening, or presence of a thyroid nodule detected on physical examination that has not been fully evaluated
• Thyroid hormone therapy that has not been stable for ≥6 weeks prior to Screening
• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2)
• History of acute or chronic pancreatitis
• Subjects taking medications that are known to affect autonomic function need to be at a stable dose of those medications ≥ 3 months prior to inclusion in the study
• Other clinically significant, active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary or hematological system that, in the opinion of the investigator, would compromise the subject's participation in the study, might confound the results of the study or pose additional risk in administering the study drug
• Recurrent severe hypoglycemia and/or hypoglycemia unawareness.
• Concurrent participation in another clinical trial with use of an experimental drug or device within 30 days of study entry.
• Known or suspected history of alcohol or substance abuse
• Mental incapacity, unwillingness or language barrier precluding adequate understanding of or cooperation with the study.
• Women of childbearing potential (WOCBP*) who are pregnant, breast-feeding or intend to become pregnant

Where it is running

• Strelitz Diabetes Center — Norfolk, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.